Standardizing human sample identification using automated genomic microfluidic systems that reduce hands-on time and cost per sample
SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ Sample ID Genotyping Panel for the identification and quality assessment of human samples and cell lines in disease research.
Maintaining accurate chain-of-custody from sample acquisition to data analysis is of paramount importance in translational and clinical research programs. During the course of each study, samples can be stored in a centralized facility and portions of each sample may be distributed to a number of different service providers, collaborating academic institutions, and pharmaceutical companies for analysis. Implementation of a standardized genotyping workflow to confirm the identity and quality of each sample prior to analysis represents an ideal solution to maximize the integrity of study results.
Developed for use with the Biomark™ HD system, the Advanta Sample ID Genotyping Panel enables laboratories to accurately detect a unique genetic fingerprint from each sample at each stage of the sample journey. The panel design contains 96 different single-nucleotide polymorphism (SNP) variants, including 80 synonymous human variants located in exonic regions of the genome, 10 quality assessment variants, and six gender-confirming variants. New targets for specific sample populations can also be easily added to customize the panel based on specific study goals.
By utilizing the high-performing Biomark HD system, which supports gene expression, genotyping, copy number variation and digital PCR analysis using Fluidigm microfluidic technology, the Advanta Sample ID Genotyping Panel workflow offers a number of additional benefits to sample identification including decreased hands-on time and significant cost savings compared to traditional qPCR methods.
“Representing an expansion of our sample identification product offering for use with Fluidigm automated microfluidic systems, the Advanta Sample ID Genotyping Panel was developed with standardization in mind,” said Chris Linthwaite, President and CEO of Fluidigm. "Designed for use with a range of genomic workflows including targeted, exome, and genome sequencing, it can help researchers power groundbreaking translational and clinical research programs across a range of disease areas with greater confidence."
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm, the Fluidigm logo, Advanta, and Biomark are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and other countries.
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423
Source: Fluidigm Corporation